Follow-up observation of rectal cancer patients with clinical complete response receiving non-operative and standard operative management after neo-adjuvant chemoradiotherapy
Department of Radiation Oncology (Zhang S,Wei JW,Xiao WW,Wang QX,Chang H,Zeng ZF,Gao YH),Department of Colorectal Surgery (Ding PR,Chen G,Pan ZZ),Sun Yat-sen University Cancer Center,State Key laboratory of Oncology in South China,Guangzhou 510060,China
Abstract： Objective To investigate the feasibility of non-operative management (NOM) by comparing the therapeutic effects between NOM and total mesorectal excision (TME) for rectal cancer patients with clinical complete response (cCR) after neo-adjuvant chemoradiotherapy. Methods A total of 135 patients with stage Ⅱ/Ⅲ rectal cancer who obtained cCR after neo-adjuvant chemoradiotherapy in Sun Yat-sen University Cancer Center from 2006 to 2016 were recruited and assigned into the NOM (n=43) and standard operative management (SOM) groups (n=92). The local recurrence rate,accumulative local control (LC) rate after salvage therapy,disease-free survival (DFS),overall survival (OS) and sphincter preservation rate were statistically compared between two groups. Kaplan-Meier analysis and log-rank test were utilized to calculate the LC, OS and DFS.Chi-square test was performed to calculate the sphincter preservation rate. Results The mean follow-up duration was 39 months (range:10-127 months).Of 135 patients, the local recurrence rate and distant metastasis rate were 3.7% and 11.1%,and the 3-year DFS and OS were 90.5% and 97.0%.In the NOM and SOM groups, the 3-year DFS were 87% and 93%, and the 5-year DFS were 73% and 87%(P=0.089).The 3-year OS were 98% and 99%, and the 5-year OS were 98% and 97%(P=0.578).In the NOM group, the local recurrence rate was 12%(n=5),80% of patients received salvage treatment and the accumulative LC rate was calculated as 98%.In the SOM group, the local recurrence rate was 0, which was significantly lower than that in the NOM group (P=0.010).In the NOM group, the sphincter preservation rate was 93%, significantly higher compared with 70% in the SOM group (P=0.030). Conclusions It is feasible for rectal cancer patients with cCR to receive NOM following neo-adjuvant chemoradiotherapy. Partial locally recurrent patients can be healed by timely salvage therapy,thereby averting TME and relevant complications and enhancing the quality of life of rectal cancer patients.
Zhang Shu,Wei Jiawang,Xiao Weiwei et al. Follow-up observation of rectal cancer patients with clinical complete response receiving non-operative and standard operative management after neo-adjuvant chemoradiotherapy[J]. Chinese Journal of Radiation Oncology, 2018, 27(4): 374-377.
[1] Renehan AG,Malcomson L,Emsley R,et al. Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project):a propensity-score matched cohort analysis[J].Lancet Oncol,2016,17(2):174-183.DOI:10.1016/S1470-2045(15)00467-2. [2] Habr-Gama A,Perez RO,Nadalin W,et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy[J].Ann Surg,2004,240(4):309-316.DOI:10.1097/01.sla.0000141194.27992.32. [3] Smith JD,Ruby JA,Goodman KA,et al. Nonoperative management of rectal cancer with complete clinical response after neoadjuvant therapy[J].Ann Surg,2012,256(6):965-972.DOI:10.1097/SLA.0b013e3182759f1c. [4] Maas M,Lambregts DMJ,Nelemans PJ,et al. Assessment of clinical complete response after chemoradiation for rectal cancer with digital rectal examination,endoscopy,and mri:selection for organ-saving treatment[J].Ann Surg Oncol,2015,22(12):3873-3880.DOI:10.1245/s10434-015-4687-9. [5] Gao YH,Lin JZ,An X,et al. Neoadjuvant sandwich treatment with oxaliplatin and capecitabine administered prior to,concurrently with,and following radiation therapy in locally advanced rectal cancer:a prospective phase 2 trial[J].Int J Radiat Oncol Biol Phys,2014,90(5):1153-1160.DOI:10.1016/j.ijrobp.2014.07.021. [6] Gao YH,An X,Sun WJ,et al. Evaluation of capecitabine and oxaliplatin administered prior to and then concomitant to radiotherapy in high risk locally advanced rectal cancer[J].J Surg Oncol,2014,109(5):478-482.DOI:10.1002/jso.23516. [7] Maas M,Nelemans PJ,Valentini V,et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer:a pooled analysis of individual patient data[J].Lancet Oncol,2010,11(9):835-844.DOI:10.1016/S1470-2045(10)70172-8. [8] Neuman HB,Elkin EB,Guillem JG,et al. Treatment for patients with rectal cancer and a clinical complete response to neoadjuvant therapy[J].Dis Colon Rec,2009,52(5):863-871.DOI:10.1007/DCR.0b013e31819eefba. [9] Park IJ,You YN,Agarwal A,et al. Neoadjuvant treatment response as an early response indicator for patients with rectal cancer[J].J Clin Oncol,2012,30(15):1770-1776. DOI:10.1200/JCO.2011.39.7901. [10] Sammour T,Price BA,Krause KJ,et al. Nonoperative management or ‘Watch and Wait’ for rectal cancer with complete clinical response after neoadjuvant chemoradiotherapy:a critical appraisal[J].Ann Surg Oncol,2017,24(7):1904-1915.DOI:10.1245/s10434-017-5841-3. [11] Habr-Gama A,Gama-Rodrigues J,So Julio GP,et al. Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation:impact of salvage therapy on local disease control[J].Int J Radiation Oncol Biol Phys,2014,88(4):822-828.DOI:10.1016/j.ijrobp.2013.12.012.
2018, Vol. 27 
